​Effective October 20, 2023, several insulin products and multiple diabetes treatment supplies have been added to the ADAP formulary. Insulin treatment products added include: insulin aspart (NovoLog®), insulin lispro (Humalog® and Admelog®), regular insulin (Humulin® R and Novolin® R), insulin detemir (Levemir®), insulin glargine (Lantus®), insulin glargine (Basaglar®). Diabetes treatment supplies added include: several glucometers, insulin delivery devices, lancets, insulin pen needles, syringes, and blood glucose test strips.

In the United States, more than 37 million adults have diabetes, and it is the seventh leading cause of death. The prevalence of diabetes in people with HIV in California is 10 percent, which is higher than the prevalence of diabetes in general population when age matched. Complications from diabetes can be prevented with a comprehensive diabetes care plan that includes appropriate diabetes supplies and medications to monitor and lower glucose levels.

People who are diagnosed with type 2 diabetes cannot effectively use insulin that their body produces. Most people with type 2 diabetes can be treated with oral diabetes medications but insulin is an important treatment option for people with severe type 2 diabetes that is not properly responding to oral medications. With access to insulin as an option to manage blood sugar levels, people with diabetes can reduce the risk of diabetes complications that may affect their heart, blood vessels, kidneys, eyes, and nerves.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of insulin and diabetes supplies.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,